// App-Quantinova.ai

5705 : Mechanisms and therapeutic implications of hypermutation in gliomas

Researchers

Presenter

  • Mehdi Touat

Principal Investigators

  • Adam N. Boynton

  • Liam F. Spurr

  • Bryan Iorgulescu

  • Craig L. Bohrson

  • Isidro Cortes-Ciriano

  • Jack E. Geduldig

  • Kristine Pelton

  • Mary J. Lim-Fat

  • Sangita Pal

  • Shakti H. Ramkissoon

  • Frank Dubois

  • Charlotte Bellamy

  • Naomi Currimjee

  • Kenin Qian

  • Seth Malinowski

  • Aniket Shetty

  • Kin-Hoe Chow

  • Mat Verreault

  • Erell Guillerm

  • Samy Ammari

  • Frdric Beuvon

  • Karima Mokhtari

  • Agusti Alentorn

  • Caroline Dehais

  • Caroline Houillier

  • Florence Laigle-Donadey

  • Dimitri Psimaras

  • Alexandre Carpentier

  • Philippe Cornu

  • Laurent Capelle

  • Bertrand Mathon

  • Jill S. Barnholtz-Sloan

  • Arnab Chakravarti

  • Wenya L. Bi

  • Garrett M. Frampton

  • Marc Sanson

  • Brian M. Alexander

  • Andrew Cherniack

  • Patrick Y. Wen

  • David A. Reardon

  • Aurelien Marabelle

  • Peter J. Park

  • Ahmed Idbaih

  • Rameen Beroukhim

  • Pratiti Bandopadhayay

  • Franck Bielle

  • Keith L. Ligon

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Broad Institute of MIT and Harvard, Cambridge, MA

  • Harvard Medical School, Boston, MA

  • European Molecular European Bioinformatics Institute, Wellcome Genome Campus, HInxton, United Kingdom

  • Broad Institute of MIT and Harvard, Cambridge, MA

  • Foundation Medicine, Inc, Cambridge, MA

  • Sorbonne Universites, Paris, France

  • Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France

  • Gustave Roussy, Villejuif, France

  • University Paris Descartes & Hopital Necker, Paris, France

  • Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France

  • Case Western Reserve University School of Medicine, Cleveland, OH

  • Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Cleveland, OH

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • Foundation Medicine, Inc., Boston, MA

  • Sorbonne Universites, Paris, France

  • Dana-Farber Cancer Institute, Boston, MA

  • Gustave Roussy, Arcueil, France

  • Sorbonne Universites, Paris, France

  • Sorbonne Universites, Paris, France

Locations

  • United States

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mismatch repair deficiency

  • Gliomas

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Temozolomide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved